Celltrion (068270) Q4 2024 earnings summary

Executive summary

• Achieved record annual revenue of 3.56 trillion KRW in 2024, up 63.4% year-over-year, with operating profit of 492 billion KRW and OPM of 13.8%.

• Consolidated financial statements received an unqualified audit opinion under K-IFRS as of December 31, 2024 and 2023.

• Completed absorption-type merger with Celltrion Healthcare on December 28, 2023, with retrospective adjustments to provisional amounts.

• Surpassed 1 trillion KRW in quarterly revenue for the first time in 4Q24, driven by strong growth in the young product portfolio.

• Completed merger and established a new CDMO subsidiary, Celltrion BioSolutions, to expand production and service capabilities.

Financial highlights

• FY2024 consolidated sales were 3,557 billion KRW, with a gross margin of 47.3% and net profit margin of 11.8%.

• 4Q24 sales reached 1,063.6 billion KRW, up 178.0% year-over-year and 20.6% sequentially; operating profit was 196.4 billion KRW, up 967.4% year-over-year.

• Net income attributable to owners of parent: 422,692 million KRW in 2024, down from 535,648 million KRW in 2023.

• Total assets: 21,055,222 million KRW at 2024 year-end, up from 19,956,814 million KRW at 2023 year-end.

• Shareholder returns included acquisition and cancellation of significant treasury shares.

Outlook and guidance

• 2025 operating profit projected to increase 2-3 times or more, with COGS ratio expected to improve to the 20% range by 4Q25.

• Revenue guidance for 2025 set at 5 trillion KRW, driven by new product launches, cost improvements, and efficiency gains.

• OP margin expected to recover to the 30% range in 2025 as high-cost inventory is depleted and Plant 3 reaches full-scale production.

• Management continues to focus on integration post-merger and operational efficiency.